Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 mai 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory...
15 mai 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio Reports First Quarter 2019 Financial Results and Corporate Update

Initiated first Phase 3 trial, PROTECTOR 1, of RTB101 in clinically symptomatic respiratory illness; top-line data from two pivotal Phase 3 trials expected in mid-2020 Initiated Phase 1b/2a trial of...
14 mai 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio Appoints Lloyd Klickstein, M.D., Ph.D., as Chief Scientific Officer

BOSTON, May 14, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
13 mai 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio to Present RTB101 Phase 2b Clinical Trial Data at American Thoracic Society 2019 International Conference

BOSTON, May 13, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that it will present additional results from the Phase 2b trial evaluating RTB101 (dactolisib), an oral,...
09 mai 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally administered, small molecule,...
01 mai 2019 16h01 HE | Source: resTORbio, Inc.

resTORbio to Participate at Upcoming Investor Conferences in May

BOSTON, May 01, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
02 avr. 2019 08h00 HE | Source: resTORbio, Inc.

resTORbio Announces Initiation of Phase 1b/2a Trial of RTB101 in Parkinson’s Disease

BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
22 mars 2019 10h02 HE | Source: resTORbio, Inc.

resTORbio, Inc. Announces Closing Public Offering of Common Stock

BOSTON, March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
19 mars 2019 19h32 HE | Source: resTORbio, Inc.

resTORbio, Inc. Announces Pricing of Public Offering of Common Stock

BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...
18 mars 2019 16h17 HE | Source: resTORbio, Inc.

resTORbio, Inc. Announces Proposed Public Offering of Common Stock

BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the...

Page précédente